Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® HIV / AIDS specialty page provides HIV/AIDS-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


Does Cabotegravir Interact with Any Other Medications?
Alex Rinehart, PhD, explains if cabotegravir interacts with any other medications.
Latest Results of the Population-Based HIV Impact Assessment Project
Jessica Justman, MD, reveals the latest results of the Population-based HIV Impact Assessment Project (2017).
Who is the Target Population for Cabotegravir?
Alex Rinehart, PhD, identifies the target population for cabotegravir.
Why is the Population-based HIV Impact Assessment Project Important?
Jessica Justman, MD, shares why the Population-based HIV Impact Assessment Project is so important.
Is Cabotegravir a Gender-Neutral PrEP Medication?
Alex Rinehart, PhD, explains how cabotegravir is a gender-neutral pre-exposure prophylaxis medication.
Societal Challenges Keep At-risk Individuals from Taking PrEP
Kenneth Mayer, MD, discusses some societal challenges that at-risk individuals face today that may keep them from taking pre-exposure prophylaxis.
What is the Population-based HIV Impact Assessment Project?
Jessica Justman, MD, explains the PHIA Project (population-based HIV impact assessments).
How is Janssen's New HIV-1 Vaccine Regimen Unique?
Hanneke Schuitemaker, PhD, explains what makes Janssen’s new HIV-1 vaccine regimen unique.
Influenza A (H3N2) has caused most of the illnesses in this severe flu season, but influenza B is becoming increasingly responsible for more infections as the flu season continues to hit the United States.